Page last updated: 2024-08-23

raloxifene hydrochloride and Bone Fractures

raloxifene hydrochloride has been researched along with Bone Fractures in 141 studies

Research

Studies (141)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	9 (6.38)	18.2507
2000's	103 (73.05)	29.6817
2010's	27 (19.15)	24.3611
2020's	2 (1.42)	2.80

Authors

Authors	Studies
Fukunaga, M; Hagino, H; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Tanaka, S; Uemura, Y	1
Allen, MR; Jacobson, AM; Metzger, CE; Rai, RK; Saldivar, R; Surowiec, RK; Wallace, JM	1
Barry, MJ; Cooke, M; Denberg, TD; Fitterman, N; Forciea, MA; Harris, RP; Humphrey, LL; Kansagara, D; McLean, RM; Mir, TP; Qaseem, A; Schünemann, HJ	1
Collister, D; Connelly, K; Tangri, N	1
Adamkovicova, M; Babosova, R; Galbavy, D; Grosskopf, B; Lukacova, M; Martiniakova, M; Mondockova, V; Omelka, R	1
Allen, MR; Berman, A; Powell, KM; Pulliam, A; Skaggs, C; Wallace, JM	1
Amling, M; Beil, FT; Ignatius, A; Jeschke, A; Khadem, S; Marshall, RP; Pogoda, P; Spiro, AS	1
Fu, R; Griffin, JC; Nelson, HD; Smith, ME	1
Kulkarni, PM; Li, W; Qu, Y	1
Cai, Z; Tsujimoto, M; Uesaka, H	1
Diab, DL; Watts, NB	1
Alam, J; Burge, R; Gold, DT; Naegeli, AN; Shen, W; Shih, T; Silverman, S	1
Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V	1
Burge, R; Flynn, JA; Fujiwara, S; Graham-Clarke, P; Hamaya, E; Sato, M	1
Abrahamsen, B; Hoff, M; Langhammer, A; Meyer, HE; Schei, B; Skurtveit, S; Syversen, U; Søgaard, AJ	1
Compston, J	2
Fan, CP; Li, Z; Mellström, D; Modi, A; Sajjan, S; Salomonsson, S; Waern, E; Yang, X	1
Mershon, JL; Schoenfeld, MJ; Stock, JL	1
Chao, HT; Cheng, MH; Lee, WL; Wang, PH	1
Barrett-Connor, E; Cauley, JA; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; Mershon, J; Mosca, L; Song, J; Wenger, NK	1
Abrahamsen, B; Eiken, P; Roerholt, C	1
Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L	1
Ohta, H	4
Laroche, M	1
Pepersack, T	1
Verhaar, HJ	1
Inaba, M; Shidara, K	1
Alexander, IM	1
Blond, B	1
Azuma, K	1
Rawlins, S	1
Altunay, H; Bilgili, H; Gecit, MR; Keskin, D; Tasci, A	1
Fu, R; Griffin, JC; Humphrey, L; Nelson, HD; Nygren, P; Smith, ME	1
Becker, C	1
Li, W; Qu, Y	1
Cochet, T; Cohade, C; Pouillès, JM; Ribot, C; Trémollieres, F	1
Borgström, F; Burge, RT; Ivergård, M; Kanis, J; Ström, O; Tosteson, AN	1
Brandi, ML	1
Arnsten, JH; Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Melamed, ML; Neugarten, J; Silbiger, SR	1
Vogel, VG	1
Schmidt, C	1
Mori, S	1
Langdahl, B; Mosekilde, L; Vestergaard, P	1
Hadji, P	1
Pouillès, JM; Ribot, C; Trémollières, F	1
Pols, HA; Wittenberg, J	1
Välimäki, MJ	1
Akiyama, T; Cao, Y; Komatsubara, S; Ma, L; Mashiba, T; Miyamoto, K; Mori, S; Norimatsu, H; Sato, M; Shi, L; Westmore, MS	1
Baranauskaite, A; Savickiene, A	1
Begerow, B; Minne, HW; Pfeifer, M; Pollähne, W	1
Delmas, PD; Fontana, A	1
Begerow, B; Minne, HW; Pfeifer, M	1
Reincke, M	1
Felsenberg, D; Glüer, CC; Mühlenbacher, D; Nickelsen, T; Pavo, I; Payer, J; Quail, D; Reginster, JY; Resch, H; Schmitt, H; Stepan, J	1
Martens, MG	1
Adachi, JD; Crans, GG; Delmas, PD; Genant, HK; Siris, E; Stock, JL; Wong, M	1
Yoh, K	1
Franzson, L; Hansdóttir, H; Prestwood, K; Sigurdsson, G	1
Cheung, AM; Diaz-Granados, N; Dodin, S; Feig, DS; Kapral, M	1
McCombs, JS; McLaughlin-Miley, C; Shi, J; Thiebaud, P	1
László, A	1
Del Puente, A; Esposito, A; Lello, S; Migliaccio, S; Ott, SM	1
Zizic, TM	1
Nakamura, T	1
Hagino, H	1
Miki, T; Tomiyoshi, Y	1
Hamaya, E; Kobayashi, H	1
Hosking, DJ; Pande, I	1
Brewer, N; Davis, S; De Nigris, E; Jones, ML; Oakley, J; Stevenson, M	1
Diehr, S; Mijal, S; Nashelsky, J	1
Adachi, JD; Cranney, A	1
Cummings, SR; Diez-Perez, A; Eastell, R; Goemaere, S; Harris, ST; Kulkarni, PM; Qu, Y; Siddhanti, SR; Siris, ES; Song, J; Stock, JL; Wong, M; Zanchetta, JR	1
Case, M; Qu, Y	1
Sambrook, P	1
Takada, J	1
Devogelaer, JP; Reginster, JY	1
Duerring, SA; Emmett, MK; Lester, MD; Pfister, AK; Saville, PD; Welch, CA	1
de Vernejoul, MC	1
Audran, M; Chappard, D; Hoppé, E; Legrand, E	1
Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Lippman, SM; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N	1
Miki, T; Tamura, A	1
Hamaya, E; Huang, QR; Liu, JL; Morii, H; Nakamura, T; Qu, Y; Thiebaud, D; Zhu, HM	1
Kaji, H; Sugimoto, T	1
Kim, SH; Oh, JM; Shin, HT; Shin, WG; Song, EK; Yeom, JH	1
Qu, Y; Sarkar, S	1
Adami, S; Agnusdei, D; Gentilella, R; Iori, N; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Sinigaglia, L	1
Roux, C	1
Barna, A; Bourgoin, M; Briot, K; Chapurlat, R; Christin-Maitre, S; Cortet, B; Costagliola, D; Diebolt, V; Dumarcet, N; Lacoin, F; Letombe, B; Nouyrigat, E; Oberlin, F; Orcel, P; Ravaud, P; Roux, C; Seret, P; Thomas, T; Veyries, ML; Vogel, JY; Yoldjian, I	1
Cauley, JA; Gaich, CL; Kendler, D; Kulkarni, PM; Lewiecki, EM; Lorraine, J; Plouffe, L; Qu, Y; Recker, RR; Recknor, CP; Rooney, TW; Stock, JL; Utian, WH; Wong, M	1
Minshall, ME; Moses, KH; Shen, W; Silverman, SL; Xie, S	1
Järvinen, TL; Kannus, P; Sievänen, H	1
Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L	1
Allen, MR; Burr, DB; Hobbs, WA; Hogan, HA; Koivuniemi, AS; Koivuniemi, MC	1
Rizzoli, R	1
Agnusdei, D; Barrett-Connor, E; Cauley, JA; Ensrud, KE; Grady, D; Khaw, KT; Mosca, L; Stock, JL; Zhao, Q	1
González Macías, J; Olmos Martínez, JM	1
Adami, S; Agnusdei, D; Gentilella, R; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Silvestri, S; Sinigaglia, L	1
Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M	1
Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T	1
Bush, TL; Cole, RC; Flaws, JA	1
Broy, S; Civitelli, R; Fleischmann, R; Gagel, R; Khosla, S; Lucas, M; Lukert, B; Maricic, M; Miller, P; Pacifici, R; Recker, R; Sarran, HS; Short, B; Short, MJ	1
McClung, BL	1
O'Mahony, D	1
Ullom-Minnich, P	1
Rubin, CD	1
McClung, MR	1
Arnaud, CD; Chiu, KM; Roe, EB	1
Cefalu, CA	1
Body, JJ; Sternon, J	1
Delmas, PD	1
Mincey, BA; Moraghan, TJ; Perez, EA	1
Cox, DA; Heath, H; Plouffe, L	1
Halbekath, J	1
Dijkmans, BA; Lems, WF	1
Baran, DT	1
Chapurlat, R; Delmas, PD	1
Chylova, K; Fedelesova, V	1
Grossman, LD	1
Deal, C; Lufkin, EG; Wong, M	1
Lane, NE	1
Hoon, TS; Leok, GC; Yosipovitch, G	1
McCarthy, M	1
Ettinger, B; Forsyth, B; Pressman, A; Tosteson, AN	1
Wade, JP	1
Pfeilschifter, J	1
McClung, B; McClung, M	1
Bauer, DC; Chapurlat, RD; Cummings, SR; Ewing, SK	1
Bruder, JM; Rubin, CD; Wang, CY	1
Sherman, S	1
Cummings, SR	1
Hayashi, Y	1

Reviews

64 review(s) available for raloxifene hydrochloride and Bone Fractures

Article	Year
Fracture risk and treatment in chronic kidney disease. Current opinion in nephrology and hypertension, 2018, Volume: 27, Issue:3 Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Risk Factors	2018
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Annals of internal medicine, 2013, Apr-16, Volume: 158, Issue:8 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Fractures, Bone; Humans; Medication Adherence; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; Thromboembolism; Treatment Outcome	2013
Postmenopausal osteoporosis. Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:6 Topics: Accidental Falls; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium; Denosumab; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Risk Reduction Behavior; Teriparatide; Vitamin D; Zoledronic Acid	2013
Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia). Clinical interventions in aging, 2014, Volume: 9 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Fractures, Bone; Hip Joint; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	2014
Emerging therapeutic concepts for muscle and bone preservation/building. Bone, 2015, Volume: 80 Topics: Anabolic Agents; Animals; Bone Density; Bone Remodeling; Bone Resorption; Denosumab; Diphosphonates; Fractures, Bone; Humans; Muscle, Skeletal; Osteoporosis; Raloxifene Hydrochloride	2015
Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas, 2008, Jun-20, Volume: 60, Issue:2 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
[Role of estrogen and selective estrogen receptor modulators in anti-aging]. Clinical calcium, 2008, Volume: 18, Issue:7 Topics: Aging; Animals; Bone and Bones; Bone Density; Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis; Perimenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators	2008
Treatment of osteoporosis: all the questions we still cannot answer. The American journal of medicine, 2008, Volume: 121, Issue:9 Topics: Age Factors; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Hormone Replacement Therapy; Humans; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Teriparatide; Thiophenes; Time Factors	2008
[Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis]. Clinical calcium, 2008, Volume: 18, Issue:10 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2008
[Treatment of osteoporosis in octogenarians]. Revue medicale de Bruxelles, 2008, Volume: 29, Issue:4 Topics: Aged, 80 and over; Attitude to Health; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Fractures, Bone; Frail Elderly; Humans; Osteoporosis; Perception; Raloxifene Hydrochloride	2008
[Bone metabolic marker for osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5 Topics: Acid Phosphatase; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Diphosphonates; Female; Fractures, Bone; Humans; Isoenzymes; Osteoporosis; Peptides; Raloxifene Hydrochloride; Risk Assessment; Tartrate-Resistant Acid Phosphatase	2009
[Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5 Topics: Bone and Bones; Bone Density; Clinical Trials as Topic; Evidence-Based Medicine; Fractures, Bone; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2009
Pharmacotherapeutic management of osteoprosis and osteopenia. The Nurse practitioner, 2009, Volume: 34, Issue:6 Topics: Algorithms; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Diphosphonates; Drug Monitoring; Estrogen Replacement Therapy; Fractures, Bone; Humans; Mass Screening; Nurse Practitioners; Nursing Assessment; Osteoporosis; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Teriparatide	2009
[Therapeutic considerations on secondary osteoporosis caused by diabetes mellitus]. Clinical calcium, 2009, Volume: 19, Issue:9 Topics: Bone Density Conservation Agents; Diabetes Complications; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D; Vitamin K	2009
Approaches to osteoporosis: screening and implementing treatment in clinical practice. The Journal of family practice, 2009, Volume: 58, Issue:7 Suppl Os Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Mass Screening; Medication Adherence; Osteoporosis; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment	2009
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Annals of internal medicine, 2009, Nov-17, Volume: 151, Issue:10 Topics: Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Norpregnenes; Raloxifene Hydrochloride; Stroke; Tamoxifen; Thromboembolism	2009
Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis. Current medical research and opinion, 2010, Volume: 26, Issue:11 Topics: Aged; Bone Density Conservation Agents; Cervical Vertebrae; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Thiophenes; Treatment Outcome	2010
[Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases]. Clinical calcium, 2011, Volume: 21, Issue:5 Topics: Adrenergic beta-Antagonists; Animals; Cardiovascular Diseases; Diabetes Complications; Diphosphonates; Dyslipidemias; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Life Style; Osteogenesis; Osteoporosis; Raloxifene Hydrochloride; Thiazolidinediones; Vitamin D	2011
Fracture prevention in postmenopausal women. BMJ clinical evidence, 2011, May-03, Volume: 2011 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Calcium, Dietary; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Incidence; Postmenopause; Raloxifene Hydrochloride	2011
The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes	2012
[Osteoporosis: prevention of bone loss and fractures]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, Differential; Exercise; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Time Factors; Tomography, X-Ray Computed	2002
Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinology and metabolism clinics of North America, 2003, Volume: 32, Issue:1 Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2003
[Rehabilitation in osteoporosis]. Deutsche medizinische Wochenschrift (1946), 2003, Apr-25, Volume: 128, Issue:17 Topics: Alendronate; Ergonomics; Exercise Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Pain; Physical Therapy Modalities; Psychotherapy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spine	2003
Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review. The Journal of reproductive medicine, 2003, Volume: 48, Issue:6 Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors	2003
[Quality of life before and after medical treatments in osteoporosis patients]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Fractures, Bone; Humans; Osteoporosis; Quality of Life; Raloxifene Hydrochloride; Sickness Impact Profile; Surveys and Questionnaires; Vitamin D	2004
[Postmenopausal osteoporosis]. Orvosi hetilap, 2004, Jan-04, Volume: 145, Issue:1 Topics: Absorptiometry, Photon; Anabolic Agents; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Isoflavones; Motor Activity; Norpregnenes; Osteoporosis, Postmenopausal; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D; Weight-Bearing	2004
A reappraisal of therapeutic approaches to osteoporosis. Aging clinical and experimental research, 2004, Volume: 16 Suppl, Issue:3 Topics: Alkaline Phosphatase; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2004
Pharmacologic prevention of osteoporotic fractures. American family physician, 2004, Oct-01, Volume: 70, Issue:7 Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators	2004
[Who are the candidates for the treatment by raloxifen ?]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Age Factors; Alendronate; Bone and Bones; Bone Density; Diet Therapy; Drug Therapy, Combination; Exercise Therapy; Female; Fractures, Bone; Humans; Motor Activity; Osteoporosis, Postmenopausal; Parathyroid Hormone; Patient Selection; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2004
[Evaluation of osteoporosis treatment efficacy by bone mass measurement]. Clinical calcium, 2004, Volume: 14, Issue:12 Topics: Absorptiometry, Photon; Bone Density; Diphosphonates; Drug Monitoring; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Treatment Outcome	2004
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2005, Volume: 125, Issue:1 Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Controlled Clinical Trials as Topic; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stroke; Transcription Factors	2005
Oral antiresorptive therapy. Current rheumatology reports, 2005, Volume: 7, Issue:1 Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide	2005
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health technology assessment (Winchester, England), 2005, Volume: 9, Issue:22 Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide	2005
Raloxifene for prevention of osteoporotic fractures. American family physician, 2005, Jul-01, Volume: 72, Issue:1 Topics: Evidence-Based Medicine; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Patient Selection; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2005
Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug safety, 2005, Volume: 28, Issue:8 Topics: Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators	2005
Who will benefit from treatment with selective estrogen receptor modulators (SERMs)? Best practice & research. Clinical rheumatology, 2005, Volume: 19, Issue:6 Topics: Aged; Bone Density; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2005
[Application of anti-resorptive drugs for the treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:2 Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid	2006
Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clinical orthopaedics and related research, 2006, Volume: 443 Topics: Animals; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2006
[Effect of raloxifene as a SERM on bone metabolism]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 4 Topics: Bone and Bones; Bone Density; Bone Resorption; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
[SERMs for treatment of osteoporosis: state-of-the-art and perspectives]. Gynecologie, obstetrique & fertilite, 2006, Volume: 34, Issue:5 Topics: Breast Neoplasms; Female; Fractures, Bone; France; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
[Postmenopausal osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Jun-28, Volume: Suppl 2 Topics: Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride	2006
[Anabolic treatment for osteoporosis: PTH treatment]. Clinical calcium, 2006, Volume: 16, Issue:9 Topics: Anabolic Agents; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Fractures, Bone; Humans; Organometallic Compounds; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Thiophenes	2006
[Drug treatment of postmenopausal osteoporosis. What's New in 2006]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:10 Pt 2 Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femoral Fractures; Follow-Up Studies; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Tablets; Teriparatide; Thiophenes; Time Factors	2006
[Osteoporosis in cancer survivors]. Medicina clinica, 2007, Nov-10, Volume: 129, Issue:17 Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fractures, Bone; Humans; Hypogonadism; Male; Middle Aged; Neoplasms; Osteoporosis; Prostatic Neoplasms; Radiotherapy; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors	2007
Management of postmenopausal osteoporosis for primary care. Menopause (New York, N.Y.), 1998,Summer, Volume: 5, Issue:2 Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Family Practice; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Referral and Consultation; Risk Factors; Sodium Fluoride	1998
Using osteoporosis management to reduce fractures in elderly women. The Nurse practitioner, 1999, Volume: 24, Issue:3 Topics: Accidental Falls; Aged; Calcitonin; Calcium; Estrogen Antagonists; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Geriatric Assessment; Humans; Nutritional Physiological Phenomena; Osteoporosis, Postmenopausal; Patient Education as Topic; Piperidines; Raloxifene Hydrochloride; Risk Factors	1999
Prevention of osteoporosis and fractures. American family physician, 1999, Volume: 60, Issue:1 Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Vitamin D	1999
Treatment considerations in the management of age-related osteoporosis. The American journal of the medical sciences, 1999, Volume: 318, Issue:3 Topics: Age Factors; Aged; Bone Density; Calcitonin; Calcium; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Severity of Illness Index	1999
Selective estrogen receptor modulators and postmenopausal health. Advances in internal medicine, 2000, Volume: 45 Topics: Breast Neoplasms; Chemoprevention; Dementia; Female; Fractures, Bone; Heart Diseases; Humans; Lipoproteins; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health	2000
Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic proceedings, 2000, Volume: 75, Issue:8 Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Ovary; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2000
[Drug treatment for the treatment of primary osteoporosis]. Zeitschrift fur arztliche Fortbildung und Qualitatssicherung, 2000, Volume: 94, Issue:6 Topics: Alendronate; Fluorides; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2000
Prevention of osteoporotic fractures in post-menopausal women. Bailliere's best practice & research. Clinical endocrinology & metabolism, 2000, Volume: 14, Issue:2 Topics: Calcitonin; Calcium; Diphosphonates; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D	2000
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures]. Nederlands tijdschrift voor geneeskunde, 2000, Oct-07, Volume: 144, Issue:41 Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Osteoporosis, Postmenopausal; Postmenopause; Radiography; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Injuries; Spine	2000
Osteoporosis: which current treatments reduce fracture risk? Cleveland Clinic journal of medicine, 2000, Volume: 67, Issue:10 Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators	2000
[Therapeutic strategies for osteoporosis]. Annales de medecine interne, 2000, Volume: 151, Issue:6 Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Nutritional Physiological Phenomena; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D	2000
The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheumatic diseases clinics of North America, 2001, Volume: 27, Issue:1 Topics: Aged; Animals; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2001
An update on glucocorticoid-induced osteoporosis. Rheumatic diseases clinics of North America, 2001, Volume: 27, Issue:1 Topics: Animals; Bone Density; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Estrogens; Fractures, Bone; Glucocorticoids; Humans; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Sodium Fluoride; United Kingdom	2001
Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Archives of dermatology, 2001, Volume: 137, Issue:4 Topics: Adult; Age Factors; Aged; Calcitonin; Calcium; Controlled Clinical Trials as Topic; Densitometry; Diphosphonates; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Exercise; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Skin Diseases; Time Factors; Vitamin D	2001
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. Southern medical journal, 2001, Volume: 94, Issue:6 Topics: Bone Density; Calcium; Consensus Development Conferences, NIH as Topic; Female; Fractures, Bone; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; United States; Vitamin D	2001
[Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis]. Der Orthopade, 2001, Volume: 30, Issue:7 Topics: Administration, Oral; Age Factors; Aged; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors; Uterine Neoplasms	2001
Pharmacologic therapy for the treatment and prevention of osteoporosis. The Nursing clinics of North America, 2001, Volume: 36, Issue:3 Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Patient Selection; Primary Prevention; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2001
Evaluation and treatment of postmenopausal osteoporosis. The American journal of managed care, 2001, Sep-25, Volume: 7 Spec No Topics: Aged; Algorithms; Bone Density; Calcitonin; Calcium; Diphosphonates; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; United States; Women's Health	2001
Preventing and treating osteoporosis: strategies at the millennium. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
[Advancement of treatment for osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 3 Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Osteoporosis; Raloxifene Hydrochloride; Vitamin K 2	2002

Trials

14 trial(s) available for raloxifene hydrochloride and Bone Fractures

Article	Year
Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene. Calcified tissue international, 2023, Volume: 112, Issue:4 Topics: Aged; Bone Density; Bone Density Conservation Agents; Cholesterol; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2023
Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study. Health and quality of life outcomes, 2013, Nov-05, Volume: 11 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Australia; Bone Density Conservation Agents; Cervical Vertebrae; European Union; Female; Forecasting; Fractures, Bone; Health Status; Humans; Middle Aged; New Zealand; North America; Osteoporosis, Postmenopausal; Patient Satisfaction; Quality of Life; Raloxifene Hydrochloride; Surveys and Questionnaires	2013
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. Journal of the National Cancer Institute, 2008, Jun-18, Volume: 100, Issue:12 Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Incidence; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Osteoporosis, Postmenopausal; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Spine	2008
Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney international, 2011, Volume: 79, Issue:2 Topics: Aged; Creatinine; Double-Blind Method; Female; Fractures, Bone; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Selective Estrogen Receptor Modulators	2011
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2003, Volume: 14, Issue:9 Topics: Adult; Aged; Analysis of Variance; Anthropometry; Bone Density; Bone Diseases, Metabolic; Double-Blind Method; Drug Therapy, Combination; Female; Fluorides; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphates; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone, 2003, Volume: 33, Issue:4 Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Recurrence; Risk Factors; Spinal Fractures	2003
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:9 Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Female; Femoral Neck Fractures; Femur Neck; Fracture Healing; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Poisson Distribution; Postmenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Risk; Time Factors; Treatment Outcome	2005
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, Jun-21, Volume: 295, Issue:23 Topics: Adult; Aged; Breast Neoplasms; Cataract; Cause of Death; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Myocardial Ischemia; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombosis; Uterine Neoplasms	2006
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone, 2007, Volume: 40, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Safety	2007
Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. The Journal of rheumatology, 2007, Volume: 34, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cross-Sectional Studies; Depression; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prevalence; Quality of Life; Raloxifene Hydrochloride; Spinal Injuries; Treatment Outcome; Vitamin D	2007
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2008, Volume: 23, Issue:1 Topics: Aged; Coronary Disease; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Spinal Fractures	2008
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei medical journal, 2008, Feb-29, Volume: 49, Issue:1 Topics: Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Humans; Lipid Metabolism; Osteoporosis; Phosphorus; Raloxifene Hydrochloride; Spine	2008
[Treatment of postmenopausal osteoporosis with raloxifene]. Bratislavske lekarske listy, 2000, Volume: 101, Issue:9 Topics: Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
Influence of smoking on the antiosteoporotic efficacy of raloxifene. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:9 Topics: Biomarkers; Bone and Bones; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hormones; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Smoking	2001

Other Studies

63 other study(ies) available for raloxifene hydrochloride and Bone Fractures

Article	Year
Ex vivo exposure to calcitonin or raloxifene improves mechanical properties of diseased bone through non-cell mediated mechanisms. Bone, 2023, Volume: 173 Topics: Animals; Bone Density Conservation Agents; Calcitonin; Fractures, Bone; Male; Mice; Mice, Inbred C57BL; Raloxifene Hydrochloride; Water	2023
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Annals of internal medicine, 2017, 06-06, Volume: 166, Issue:11 Topics: Bone Diseases, Metabolic; Calcium, Dietary; Denosumab; Diphosphonates; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Vitamin D	2017
The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women. BMC medical genetics, 2018, 09-21, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Estradiol; Estrogen Receptor alpha; Estrogen Replacement Therapy; Female; Femur Neck; Fractures, Bone; Gene Expression; Genotype; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Polymorphism, Single Nucleotide; Postmenopause; Progesterone; Raloxifene Hydrochloride; Slovakia; Treatment Outcome	2018
Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone. Bone, 2019, Volume: 127 Topics: Animals; Biomechanical Phenomena; Bone Diseases; Calcification, Physiologic; Cancellous Bone; Diaphyses; Drug Therapy, Combination; Femur; Fractures, Bone; Male; Mice, Inbred C57BL; Raloxifene Hydrochloride; Zoledronic Acid	2019
The SERM raloxifene improves diaphyseal fracture healing in mice. Journal of bone and mineral metabolism, 2013, Volume: 31, Issue:6 Topics: Animals; Diaphyses; Estrogens; Female; Femoral Fractures; Femur; Fracture Healing; Fractures, Bone; Humans; Mice; Mice, Inbred C57BL; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2013
Sensitivity in statistical evaluation of biomarkers. Statistics in medicine, 2013, Sep-20, Volume: 32, Issue:21 Topics: Biomarkers; Biomedical Research; Computer Simulation; Data Interpretation, Statistical; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2013
Comparison of two ethnic populations using distribution adjusted mean. Journal of biopharmaceutical statistics, 2013, Volume: 23, Issue:3 Topics: Algorithms; Analysis of Variance; Bone Density; Computer Simulation; Cross-Cultural Comparison; Data Interpretation, Statistical; Ethnicity; Fractures, Bone; Humans; Japan; Monte Carlo Method; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Sample Size; Selective Estrogen Receptor Modulators; Treatment Outcome	2013
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid	2014
Use of anti-osteoporotic drugs in central Norway after a forearm fracture. Archives of osteoporosis, 2015, Volume: 10 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Prescriptions; Female; Forearm; Forearm Injuries; Fractures, Bone; Glucocorticoids; Humans; Male; Middle Aged; Norway; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Secondary Prevention; Teriparatide	2015
Proportion and Characteristics of Patients in Sweden Remaining at High Risk of Fracture Despite Prior Treatment. Clinical therapeutics, 2016, Volume: 38, Issue:7 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk; Sweden	2016
Review of comparative effectiveness of treatments to prevent fractures. Annals of internal medicine, 2008, Jun-03, Volume: 148, Issue:11 Topics: Bone Density Conservation Agents; Cardiovascular Diseases; Clinical Trials as Topic; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride	2008
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Drug Prescriptions; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Patient Compliance; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Sex Distribution; Spinal Fractures; Treatment Outcome	2009
Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Confounding Factors, Epidemiologic; Dietary Supplements; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk; Treatment Outcome; Vitamin D; Vitamin D Deficiency	2009
[Treatment of osteoporosis in the elderly: what is the evidence?]. Tijdschrift voor gerontologie en geriatrie, 2008, Volume: 39, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Teriparatide; Treatment Outcome	2008
[4/5. Osteoporosis]. Soins; la revue de reference infirmiere, 2009, Issue:735 Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Calcium; Fractures, Bone; Humans; Menopause; Middle Aged; Osteoporosis; Raloxifene Hydrochloride	2009
Biomechanical and histological outcome of combined raloxifene-estrogen therapy on skeletal and reproductive tissues. European journal of pharmacology, 2010, Feb-10, Volume: 627, Issue:1-3 Topics: Animals; Body Weight; Bone and Bones; Bone Density; Drug Therapy, Combination; Estrogens; Female; Femur; Fractures, Bone; Organ Specificity; Osteopetrosis; Raloxifene Hydrochloride; Rats; Rats, Wistar; Risk; Tibia; Uterus	2010
Another selective estrogen-receptor modulator for osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2010
Adjustment for the measurement error in evaluating biomarkers. Statistics in medicine, 2010, Sep-30, Volume: 29, Issue:22 Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Computer Simulation; Data Interpretation, Statistical; Evaluation Studies as Topic; Female; Fractures, Bone; Humans; Models, Statistical; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results	2010
Fracture risk in early postmenopausal women assessed using FRAX. Joint bone spine, 2010, Volume: 77, Issue:4 Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; France; Hip Fractures; Humans; Middle Aged; Models, Statistical; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors	2010
Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone, 2010, Volume: 47, Issue:5 Topics: Aged; Algorithms; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride	2010
Tipping the balance for the primary prevention of breast cancer. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confounding Factors, Epidemiologic; Estradiol; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Risk Assessment; Sample Size; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome	2010
Third-generation SERMs may face uphill battle. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration	2010
[Current therapeutic means]. Presse medicale (Paris, France : 1983), 2002, Apr-20, Volume: 31, Issue:15 Topics: Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Reproducibility of Results	2002
[CBO guideline 'Osteoporosis' (second revision]. Nederlands tijdschrift voor geneeskunde, 2002, Jul-20, Volume: 146, Issue:29 Topics: Adrenal Cortex Hormones; Age Factors; Aged; Bone Density; Calcium, Dietary; Dietary Supplements; Female; Fractures, Bone; Humans; Male; Menopause; Middle Aged; Netherlands; Osteoporosis; Practice Guidelines as Topic; Prevalence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Societies, Medical; Vitamin D	2002
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?]. Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:24 Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibility; Humans; Osteoporosis; Physician's Role; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors	2001
Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:12 Topics: Alendronate; Animals; Estrogens; Female; Fracture Healing; Fractures, Bone; Ovariectomy; Radiography; Raloxifene Hydrochloride; Rats	2002
[Osteoporosis: diagnosis, prevention and treatment]. Medicina (Kaunas, Lithuania), 2002, Volume: 38, Issue:2 Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Injections, Intramuscular; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators	2002
[Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?]. MMW Fortschritte der Medizin, 2003, Feb-27, Volume: 145, Issue:9 Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Hyperaldosteronism; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2003
[Osteoporosis therapy compared. More solid bones with bisphosphonates]. MMW Fortschritte der Medizin, 2003, Aug-07, Volume: 145, Issue:31-32 Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2003
The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:5 Topics: Acid Phosphatase; Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Collagen Type I; Data Interpretation, Statistical; Female; Fractures, Bone; Humans; Long-Term Care; Nursing Homes; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphates; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors; Vitamin D	2004
Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, May-25, Volume: 170, Issue:11 Topics: Aged; Bone Density; Diphosphonates; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Women's Health	2004
Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas, 2004, Jul-15, Volume: 48, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Health Care Costs; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors	2004
[Bone quality and raloxifene]. Clinical calcium, 2004, Volume: 14, Issue:4 Topics: Bone and Bones; Calcification, Physiologic; Fractures, Bone; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2004
Quantifying the indirect treatment effect via surrogate markers. Statistics in medicine, 2006, Jan-30, Volume: 25, Issue:2 Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Data Interpretation, Statistical; Fractures, Bone; Osteocalcin; Osteoporosis; Peptides; Proportional Hazards Models; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	2006
Cost-effectiveness strategies to treat osteoporosis in elderly women. Southern medical journal, 2006, Volume: 99, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcitonin; Cost Savings; Cost-Benefit Analysis; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis; Parathyroid Hormone; Quality of Life; Raloxifene Hydrochloride; Treatment Outcome	2006
[New therapeutic approaches to osteoporosis]. Annales d'endocrinologie, 2006, Volume: 67, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride	2006
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. Journal of bone and mineral metabolism, 2006, Volume: 24, Issue:5 Topics: Aged; Asian People; Bone Density Conservation Agents; China; Female; Fractures, Bone; Humans; Incidence; Japan; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2006
Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy. Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:5 Topics: Absorptiometry, Photon; Aged; Body Mass Index; Bone Density; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Time Factors	2006
Quantifying the treatment effect explained by markers in the presence of measurement error. Statistics in medicine, 2007, Apr-30, Volume: 26, Issue:9 Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Fractures, Bone; Humans; Logistic Models; Osteoporosis; Raloxifene Hydrochloride; Treatment Outcome	2007
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2006, Volume: 21, Issue:10 Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Italy; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Factors; Vitamin D	2006
[Osteoporosis priority: Reduce the number of fractures]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:10 Pt 2 Topics: Absorptiometry, Photon; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, Bone; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Teriparatide; Thiophenes; Time Factors	2006
Bone quality: an empty term. PLoS medicine, 2007, Volume: 4, Issue:3 Topics: Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Fractures, Bone; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2007
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC women's health, 2007, Apr-17, Volume: 7 Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Risk; Thromboembolism	2007
Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology, 2007, Volume: 148, Issue:8 Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Dogs; Female; Femur Neck; Fractures, Bone; Raloxifene Hydrochloride; Trabecular Meshwork	2007
Osteoporosis: non-hormonal treatment. Climacteric : the journal of the International Menopause Society, 2007, Volume: 10 Suppl 2 Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health	2007
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:8 Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Italy; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Treatment Failure	2008
Summaries for patients. Drug therapy for osteoporosis. Annals of internal medicine, 2008, May-06, Volume: 148, Issue:9 Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors	2008
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Annals of internal medicine, 2008, May-06, Volume: 148, Issue:9 Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors	2008
Effects of raloxifene in postmenopausal women. The New England journal of medicine, 1998, Apr-30, Volume: 338, Issue:18 Topics: Bone Density; Estrogen Antagonists; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Research Design	1998
Tamoxifen for prevention of breast cancer. The Medical letter on drugs and therapeutics, 1999, Jan-01, Volume: 41, Issue:1043 Topics: Adult; Breast Neoplasms; Cerebrovascular Disorders; Drug Costs; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Fractures, Bone; Humans; Middle Aged; Myocardial Infarction; Osteoporosis, Postmenopausal; Piperidines; Placebos; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Thrombophlebitis	1999
Prevention of corticosteroid-induced osteoporosis and fractures. Journal of clinical pharmacy and therapeutics, 1999, Volume: 24, Issue:2 Topics: Adrenal Cortex Hormones; Bone Density; Calcitonin; Calcitriol; Calcium Channel Agonists; Estrogen Antagonists; Fractures, Bone; Hormone Replacement Therapy; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride	1999
Therapy for fracture prevention. JAMA, 1999, Aug-18, Volume: 282, Issue:7 Topics: Bone Density; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk	1999
Raloxifene therapy in the reduction of fractures. American family physician, 2000, Mar-01, Volume: 61, Issue:5 Topics: Aged; Blood Coagulation Factors; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Incidence; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2000
[Raloxifene (Celvista, Evista)]. Revue medicale de Bruxelles, 2000, Volume: 21, Issue:1 Topics: Arteriosclerosis; Bone and Bones; Breast Neoplasms; Controlled Clinical Trials as Topic; Endometrium; Female; Fractures, Bone; Heart Diseases; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism; Uterine Hemorrhage	2000
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone, 2000, Volume: 27, Issue:1 Topics: Aged; Alendronate; Bone and Bones; Bone Demineralization, Pathologic; Estrogen Antagonists; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk	2000
Raloxifene therapy. Journal of the American Geriatrics Society, 2000, Volume: 48, Issue:9 Topics: Accidental Falls; Central Nervous System; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
Alendronic acid in primary prevention: new indication. No reduction in fracture risk. Prescrire international, 2000, Volume: 9, Issue:47 Topics: Alendronate; Clinical Trials as Topic; Cost-Benefit Analysis; Esophagitis; Estrogen Replacement Therapy; Female; Fractures, Bone; France; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2000
Drug information needs clarification. Canadian family physician Medecin de famille canadien, 2001, Volume: 47 Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Antagonists; Female; Fractures, Bone; Humans; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Reproducibility of Results; Risk Factors	2001
Raloxifene fails to slow cognitive decline in older women. Lancet (London, England), 2001, Apr-21, Volume: 357, Issue:9264 Topics: Aged; Cognition Disorders; Female; Fractures, Bone; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Initiation of osteoporosis treatment after bone mineral density testing. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2001, Volume: 12, Issue:5 Topics: Absorptiometry, Photon; Age Factors; Aged; Bone Density; Cohort Studies; Decision Making; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Glucocorticoids; Health Care Rationing; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2001
Rheumatology: 15. Osteoporosis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Jul-10, Volume: 165, Issue:1 Topics: Bone Density; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Life Style; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thoracic Vertebrae; Vitamin D	2001
Raloxifene: new preparation. Not better than oestrogen. Prescrire international, 1999, Volume: 8, Issue:44 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms	1999
The paradox of small changes in bone density and reductions in risk of fracture with raloxifene. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Bone Density; Fractures, Bone; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001